Executive Summary

The medical technology sector is entering a period of accelerated transformation as five key trends reshape global market dynamics: China's volume-based procurement (VBP) expansion, the migration of procedures to outpatient settings, intensifying supply chain and trade pressures, the ripple effects of GLP-1 receptor agonists on care pathways, and the emergence of platform-based competition driven by enabling technologies. For Europe's medtech industry—a critical component of the region's industrial base and healthcare systems—these developments carry profound implications for corporate strategy, investment decisions, and long-term competitiveness. This article examines each trend through a European lens, drawing on insights from Clarivate's Medtech Trends to Watch 2026 report.

1. China's VBP Expansion Reshapes Global Pricing and Portfolio Strategy

China's latest national volume-based procurement (VBP) round represents a significant escalation of pricing pressure on medical devices. Originally designed to improve patient access and reduce costs, VBP has evolved into a market-structuring mechanism that now influences pricing expectations far beyond China's borders. Anchor-price logic, deeper compression, and allocation favoring domestic manufacturers challenge multinational corporations (MNCs) that have historically relied on China for growth.

European Perspective: European medtech companies—particularly those with significant exposure to orthopedics, cardiovascular, and consumables—must reassess their China strategies. The VBP-driven price erosion may accelerate portfolio rationalization, pushing MNCs to prioritize premium innovation and services over volume in China. At the same time, European firms can leverage their regulatory expertise and clinical evidence to compete in higher-value segments that may remain outside VBP. The policy also incentivizes local R&D investment in China, which could spur competition for European innovation hubs.

Business Impact: Portfolio strategy, pricing models, and R&D allocation will need to account for VBP's long-term effects. European companies with diversified geographic exposure may be better positioned, but the contagion of VBP-style purchasing to other emerging markets warrants monitoring.

2. Outpatient and Ambulatory Settings Become Central to Procedure Strategy

The shift of procedures from inpatient hospitals to outpatient settings—including ambulatory surgery centers (ASCs) and specialty clinics—continues to accelerate. In the U.S., CMS's 2026 OPPS/ASC final rule expanded the ASC covered procedure list and phased out the inpatient-only list, enabling higher-acuity procedures like cardiac ablation to move to lower-cost sites. Similar trends are evident across Europe, albeit with varying speed due to differences in healthcare financing and infrastructure.

European Perspective: European healthcare systems are increasingly adopting day surgery and outpatient models to improve efficiency and reduce costs. The OECD and national health ministries have promoted same-day discharge for procedures such as hip and knee replacements, cataract surgery, and hernia repair. This creates opportunities for medtech companies to develop devices optimized for outpatient use—smaller, easier to use, and with faster recovery profiles. It also shifts the customer base from hospital procurement departments to ASC networks and physician groups, demanding new commercial and service models.

Business Impact: Companies must adapt product design, sales force structure, and value propositions for outpatient settings. Those that can demonstrate reduced length of stay, lower complication rates, and cost savings will gain competitive advantage. The trend also favors minimally invasive technologies and digital solutions that support remote monitoring and patient engagement.

3. Global Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Supply chain resilience has become a strategic imperative amid tariffs, geopolitical tensions, and fluctuating material costs. The medtech industry, which relies on complex global supply chains for components, raw materials, and finished devices, is particularly vulnerable. European manufacturers face additional pressures from energy costs, regulatory divergence post-Brexit, and the EU's push for strategic autonomy in health.

European Perspective: The European Commission's Critical Medicines Act and proposed reforms to the Medical Device Regulation aim to strengthen domestic production of essential devices and components. However, achieving self-sufficiency is challenging given the specialized nature of medtech manufacturing. Companies are exploring multi-region sourcing, nearshoring to Eastern Europe, and increased inventory buffers. Larger players are investing in automation and digital supply chain tools to enhance flexibility.

Business Impact: Cost structures will change, with potential upward pressure on prices. Companies that can afford to diversify suppliers and build regional manufacturing hubs may gain reliability and market access advantages. SMEs, which form the backbone of European medtech, may struggle to absorb these costs, potentially driving consolidation.

4. GLP-1 Therapies Shift Patient Behavior and Reshape Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists—originally for diabetes but now widely used for obesity—is altering clinical pathways across multiple specialties. While bariatric surgery remains more effective for substantial weight loss, GLP-1s have expanded the treatment population and changed referral patterns. Downstream effects on cardiovascular, sleep apnea, and diabetes device markets are emerging.

European Perspective: European health systems have historically been more restrictive in approving GLP-1s for weight management due to cost and long-term efficacy concerns. However, recent EMA approvals and NICE recommendations are expanding access. This will likely reduce demand for certain bariatric procedures in Europe, particularly gastric banding, while increasing demand for devices that manage comorbidities such as glucose monitors, cardiac monitors, and sleep apnea masks.

Business Impact: Medtech companies should monitor volume shifts in bariatric surgery and related categories. Product portfolios may need rebalancing, and investment in metabolic disease monitoring and digital therapeutics could grow. European firms with strong diabetes care franchises are well-positioned to benefit.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer mere procedure enhancements—they are becoming core platforms that anchor entire service lines. Companies are investing in integrated ecosystems that cover planning, execution, and post-operative care. Open-platform systems are also emerging, allowing interoperability and expanding competitive dynamics.

European Perspective: Europe is home to several leading robotics and imaging companies (e.g., in surgical robotics, intraoperative imaging). The shift to platform-based competition plays to European strengths in precision engineering and software integration. However, it also requires significant R&D investment and partnerships with health systems and data analytics firms. The EU's AI Act and data governance frameworks will shape how these platforms develop, particularly in terms of data sharing and algorithm validation.

Business Impact: Platform strategies can deepen customer lock-in and create recurring revenue streams through software, service contracts, and consumables. European companies that fail to invest in digital ecosystems risk losing ground to U.S. and Asian competitors. Startups in this space may become attractive acquisition targets.

Future Outlook (2026-2030)

The next three to five years will see European medtech companies navigate a complex landscape: pricing pressure from VBP and similar policies globally, a shift to outpatient and value-based care, supply chain transformation, clinical pathway disruption, and technological convergence. Those that succeed will likely prioritize:

• Portfolio agility: Rapid adaptation to regional pricing and care setting changes.
• Operational resilience: Diversified manufacturing and supply chains.
• Platform innovation: Investment in digital and robotic ecosystems.
• Therapeutic adjacencies: Capitalizing on metabolic disease trends.

European policymakers, for their part, can support competitiveness by streamlining regulation, incentivizing domestic production of critical devices, and fostering cross-border innovation clusters. The medtech sector's ability to deliver both economic and health value will remain central to Europe's industrial strategy.

Conclusion

The five trends outlined here represent both challenges and opportunities for Europe's medtech ecosystem. By understanding their implications and deploying strategic foresight, European companies can maintain their position as global leaders in medical technology while contributing to the continent's economic resilience and innovation leadership.